

**Periphere T-Zell-Lymphome – Ein Update zu Klassifikation und Behandlungsmöglichkeiten (S. 8–14)**

*F. L. Schümann, T. Weber*

**Literatur:**

1. Swerdlow SH, World Health Organization, International Agency for Research on Cancer. WHO classification of tumours of haematopoietic and lymphoid tissues. Revised 4th edition. ed. Lyon: International Agency for Research on Cancer; 2017
2. Anderson JR, Armitage JO, Weisenburger DD. Epidemiology of the non-Hodgkin's lymphomas: distributions of the major subtypes differ by geographic locations. Non-Hodgkin's Lymphoma Classification Project. *Ann Oncol* 1998; 9(7): 717–20
3. Adams SV, Newcomb PA, Shustov AR. Racial Patterns of Peripheral T-Cell Lymphoma Incidence and Survival in the United States. *J Clin Oncol* 2016; 34(9): 963–71
4. Vose J, Armitage J, Weisenburger D, International TCLP. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. *J Clin Oncol* 2008; 26(25): 4124–30
5. Wulf G, Weber T. Periphere T-Zell-Lymphome Primär- und Rezidivtherapie. *Der Onkologe* 2019; 25: 892–8
6. Harris NL et al. The World Health Organization classification of neoplastic diseases of the haematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee Meeting, Airlie House, Virginia, November 1997. *Histopathology* 2000; 36(1): 69–86
7. Alaggio R et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. *Leukemia* 2022; 36(7): 1720–48
8. Campo E et al. The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee. *Blood* 2022; 140(11): 1229–53
9. Hopfinger G HM, deLeval L, Krasniqi F, Reimer P, Schmitz N, Wulf G. Periphere T-Zell Lymphome. *Onkopedia Leitlinie der DGHO*. 2021
10. Herling M BM, Haferlach C, Hallek M, Höller S, Hopfinger G, Stilgenbauer S, Dreger P. T-Zell Prolymphozytenleukämie. *Onkopedia Leitlinie der DGHO*. 2021
11. d'Amore F et al. Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01. *J Clin Oncol* 2012; 30(25): 3093–9
12. Ellin F, Landstrom J, Jerkeman M, Relander T. Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma Registry. *Blood* 2014; 124(10): 1570–7
13. Brink M et al. Impact of etoposide and ASCT on survival among patients aged < 65 years with stage II to IV PTCL: a population-based cohort study. *Blood* 2022; 140(9): 1009–19
14. Horwitz SM et al. The Echelon-2 Trial: 5-Year Results of a Randomized, Double-Blind, Phase 3 Study of Brentuximab Vedotin and CHP (A plus CHP) Versus CHOP in Frontline Treatment of Patients with CD30-Positive Peripheral T-Cell Lymphoma. *Blood* 2020; 136

15. Horwitz S et al. Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. *Lancet* 2019; 393(10168): 229–40
16. Park SI et al. The role of autologous stem cell transplantation in patients with nodal peripheral T-cell lymphomas in first complete remission: Report from COMPLETE, a prospective, multicenter cohort study. *Cancer* 2019; 125(9): 1507–17
17. Fossard G et al. Corrigendum to 'Role of up-front autologous stem-cell transplantation in peripheral T-cell lymphoma for patients in response after induction: an analysis of patients from LYSA centers': [Annals of Oncology Volume 29, Issue 3, March 2018, Pages 715-723]. *Ann Oncol* 2021; 32(7): 945
18. Fossard G et al. Role of up-front autologous stem-cell transplantation in peripheral T-cell lymphoma for patients in response after induction: an analysis of patients from LYSA centers. *Ann Oncol* 2018; 29(3): 715–23
19. Garcia-Sancho AM et al. Autologous stem-cell transplantation as consolidation of first-line chemotherapy in patients with peripheral T-cell lymphoma: a multicenter GELTAMO/FIL study. *Haematologica* 2022; 107(11): 2675–84
20. Schmitz N et al. A randomized phase 3 trial of autologous vs allogeneic transplantation as part of first-line therapy in poor-risk peripheral T-NHL. *Blood* 2021; 137(19): 2646–56
21. Schmitz C et al. Baseline and interim PET-based outcome prediction in peripheral T-cell lymphoma: A subgroup analysis of the PETAL trial. *Hematological Oncol* 2020; 38(3): 244–56
22. Wilhelm M et al. First-line therapy of peripheral T-cell lymphoma: extension and long-term follow-up of a study investigating the role of autologous stem cell transplantation. *Blood Cancer J* 2016; 6(7): e452
23. Reimer P et al. Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study. *J Clin Oncol* 2009; 27(1): 106–13
24. Crump M et al. Randomized Comparison of Gemcitabine, Dexamethasone, and Cisplatin Versus Dexamethasone, Cytarabine, and Cisplatin Chemotherapy Before Autologous Stem-Cell Transplantation for Relapsed and Refractory Aggressive Lymphomas: NCIC-CTG LY.12. *J Clin Oncol* 2014; 32(31): 3490
25. Schmitz N, Lenz G, Stelljes M. Allogeneic hematopoietic stem cell transplantation for T-cell lymphomas. *Blood* 2018; 132(3): 245–53
26. Mak V et al. Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors. *J Clin Oncol* 2013; 31(16): 1970–6
27. Hamadani M et al. Outcome of allogeneic transplantation for mature T-cell lymphomas: impact of donor source and disease characteristics. *Blood Adv* 2022; 6(3): 920–30
28. Smith SM et al. Hematopoietic cell transplantation for systemic mature T-cell non-Hodgkin lymphoma. *J Clin Oncol* 2013; 31(25): 3100-9
29. Damaj G et al. Results from a prospective, open-label, phase II trial of bendamustine in refractory or relapsed T-cell lymphomas: the BENTLY trial. *J Clin Oncol* 2013; 31(1): 104–10
30. Ma H, O'Connor OA, Marchi E. New directions in treating peripheral T-cell lymphomas (PTCL): leveraging epigenetic modifiers alone and in combination. *Expert Rev Hematol* 2019; 12(3): 137–46
31. Brammer JE. Dual PI3K blockade: PTCL's Achilles heel? *Blood* 2018; 131(8): 839–40

32. Horwitz S et al. The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma. *Ann Oncol* 2022; 33(3): 288–298
  33. Brammer JEZ et al. Duvelisib in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma from the Phase 2 Primo Trial: Results of an Interim Analysis. *Blood* 2021; 138: 2456
  34. Battistella M et al. KIR3DL2 (CD158k) is a potential therapeutic target in primary cutaneous anaplastic large-cell lymphoma. *Br J Dermatol* 2016; 175(2): 325–33
  35. Hurabielle C et al. KIR3DL2 expression in patients with adult T-cell lymphoma/leukaemia. *Br J Dermatol* 2018; 179(1): 197–9
  36. Moins-Teisserenc H et al. CD158k is a reliable marker for diagnosis of Sezary syndrome and reveals an unprecedented heterogeneity of circulating malignant cells. *J Invest Dermatol* 2015; 135(1): 247–57
  37. Thonnart N et al. KIR3DL2 is a coinhibitory receptor on Sezary syndrome malignant T cells that promotes resistance to activation-induced cell death. *Blood* 2014; 124(22): 3330–2
  38. Lemonnier F et al. Recurrent TET2 mutations in peripheral T-cell lymphomas correlate with TFH-like features and adverse clinical parameters. *Blood* 2012; 120(7): 1466–9
  39. Couronne L, Bastard C, Bernard OA. TET2 and DNMT3A mutations in human T-cell lymphoma. *N Engl J Med* 2012; 366(1): 95–6
  40. Cairns RA et al. IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma. *Blood* 2012; 119(8): 1901–3
  41. Dupuis J TK et al. Oral Azacytidine in Patients with Relapsed/Refractory Angioimmunoblastic T-Cell Lymphoma: Final Analysis of the Oracle Phase III Study. 6th ASH Annual Meeting and Exposition. 2022, #624
- 

## **Aktuelle Therapie der Chronischen Lymphatischen Leukämie (S. 14–18)**

*C. Schneider, E. Tausch, S. Stilgenbauer*

### **Literatur:**

1. CM Wendtner et al. Onkopedia Leitlinie Chronische Lymphatische Leukämie. (<https://www.onkopedia.com/de/onkopedia/guidelines/chronische-lymphatische-leukaemie-cll/@@guideline/html/index.html>). Zugegriffen am 16.01.2023
2. Hallek M et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. *Blood* 2018; 131(25): 2745–60
3. Rawstron AC et al. Monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia. *N Engl J Med* 2008; 359(6): 575–8
4. Eichhorst B et al. Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol* 2021; 32(1): 23–33
5. Binet JL et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. *Cancer* 1981; 48(1): 198–206

6. Hamblin TJ et al., Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. *Blood* 1999; 94(6): 1848–54
7. Dohner H et al. Genomic aberrations and survival in chronic lymphocytic leukemia. *N Engl J Med* 2000; 343(26): 1910–6
8. Stilgenbauer S et al. Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial. *Blood* 2014; 123(21): 3247–54
9. Tausch E et al. Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclax. *Blood* 2020; 135(26): 2402–12
10. Landau DA et al. Mutations driving CLL and their evolution in progression and relapse. *Nature* 2015; 526(7574): 525–30
11. Puente XS et al. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. *Nature* 2011; 475(7354): 101–5
12. Fabbri G et al. Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation. *J Exp Med* 2011; 208(7): 1389–401
13. Knisbacher BA et al. Molecular map of chronic lymphocytic leukemia and its impact on outcome. *Nat Genet* 2022; 54(11): 1664–74
14. Herling CD et al. Early treatment with FCR versus watch and wait in patients with stage Binet A high-risk chronic lymphocytic leukemia (CLL): a randomized phase 3 trial. *Leukemia* 2020; 34(8): 2038–50
15. Langerbeins P et al. The CLL12 trial: ibrutinib vs placebo in treatment-naive, early-stage chronic lymphocytic leukemia. *Blood* 2022; 139(2): 177–87
16. Eichhorst B et al. TIME-LIMITED VENETOCLAX-OBINUTUZUMAB +/- IBRUTINIB IS SUPERIOR TO CHEMOIMMUNOTHERAPY IN FRONTLINE CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): PFS CO-PRIMARY ENDPOINT OF THE RANDOMIZED PHASE 3 GAIA/CLL13 TRIAL. Presentation during EHA2022, LB2365, Late breaking abstract session, 2022
17. Barr PM et al. Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia. *Blood Adv* 2022; 6(11): 3440–50
18. Burger JA et al. Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia. *N Engl J Med* 2015; 373(25): 2425–37
19. Woyach JA et al. Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL. *N Engl J Med* 2018; 379(26): 2517–28
20. Shanafelt TD et al. Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia. *N Engl J Med* 2019; 381(5): 432–43
21. Byrd JC et al. Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial. *J Clin Oncol* 2021; 39(31): 3441–52
22. Hillmen P et al. ALPINE: zanubrutinib versus ibrutinib in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. *Future Oncol* 2020; 16(10): 517–23
23. Sharman JP et al. Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naive chronic lymphocytic leukemia. *Leukemia* 2022; 36(4): 1171–5
24. Sharman JP et al. Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial. *Lancet* 2020; 395(10232): 1278–91

25. Tam CS et al. Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial. *Lancet Oncol* 2022; 23(8): 1031–43
  26. Al-Sawaf O et al. Minimal Residual Disease Dynamics after Venetoclax-Obinutuzumab Treatment: Extended Off-Treatment Follow-up From the Randomized CLL14 Study. *J Clin Oncol* 2021; 39(36): 4049–60
  27. Fischer K et al. Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions. *N Engl J Med* 2019; 380(23): 2225–36
  28. Eichhorst B et al. A Randomized Phase III Study of Venetoclax-Based Time-Limited Combination Treatments (RVe, GVe, GIVe) Vs Standard Chemoimmunotherapy (CIT: FCR/BR) in Frontline Chronic Lymphocytic Leukemia (CLL) of Fit Patients: First Co-Primary Endpoint Analysis of the International Intergroup GAIA (CLL13) Trial. *Blood* 2021; 138(Supplement 1): 71
  29. Kater Arnon P et al. Fixed-Duration Ibrutinib-Venetoclax in Patients with Chronic Lymphocytic Leukemia and Comorbidities. *NEJM Evidence* 2022; 1(7): EVIDoa2200006
  30. Brown JR et al. Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia. *N Engl J Med* 2022
  31. Hillmen P et al. Zanubrutinib Versus Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: Interim Analysis of a Randomized Phase III Trial. *J Clin Oncol* 2022; JCO2200510
  32. Kater AP et al. Venetoclax Plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations From the MURANO Phase III Study. *J Clin Oncol* 2020; 38(34): 4042–54
  33. Seymour JF et al. Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia. *N Engl J Med* 2018; 378(12): 1107–20
  34. Stilgenbauer S et al. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study. *Lancet Oncol* 2016; 17(6): 768–78
  35. Stilgenbauer S et al. S146: VENETOCLAX IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA WITH 17P DELETION: 6-YEAR FOLLOW-UP AND GENOMIC ANALYSES IN A PIVOTAL PHASE 2 TRIAL, Abstract Book for the 27th Congress of the European Hematology Association. *HemaSphere* 2022; 6
  36. Furman RR et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. *N Engl J Med* 2014; 370(11): 997–1007
  37. Sharman JP et al. Final Results of a Randomized, Phase III Study of Rituximab With or Without Idelalisib Followed by Open-Label Idelalisib in Patients With Relapsed Chronic Lymphocytic Leukemia. *J Clin Oncol* 2019; 37(16): 1391–402
-

## Aktuelle Strategien beim fortgeschrittenen Mammakarzinom (S. 21–24)

A. Droste, M. Schmidt

### Literatur:

1. Gesellschaft der epidemiologischen Krebsregister in Deutschland / Robert Koch-Institut: Krebs in Deutschland 2015/2016, Häufigkeiten und Trends: 12. Ausgabe 2019. <http://www.gekid.de/Atlas/CurrentVersion/atlas.html>. Letzter Aufruf: 21.07.2022
2. Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF): S3-Leitlinie Früherkennung, Diagnose, Therapie und Nachsorge des Mammakarzinoms, Version 4.4, 2021, AWMF Registernummer: 032-045OL, <http://www.leitlinienprogramm-onkologie.de/leitlinien/mammakarzinom/>. Letzter Aufruf: 21.07.2022
3. Aurilio G et al. A meta-analysis of oestrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 discordance between primary breast cancer and metastases. *Eur J Cancer* 2014; 50: 277–89
4. Li J et al. Association of Cyclin-Dependent Kinases 4 and 6 Inhibitors With Survival in Patients With Hormone Receptor-Positive Metastatic Breast Cancer: A Systematic Review and Meta-analysis. *JAMA Netw Open* 2020; 3: e2020312
5. Johnston S et al. MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer. *NPJ Breast Cancer* 2019; 5: 5
6. Hortobagyi GN et al. Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer. *Ann Oncol* 2018; 29: 1541–47
7. Hortobagyi GN et al. Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer. *N Engl J Med* 2022; 386: 942–50
8. Slamon DJ et al. Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3. *J Clin Oncol* 2018; 36: 2465–72
9. Finn RS et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. *Lancet Oncol* 2015; 16: 25–35
10. Finn RS et al. Palbociclib and Letrozole in Advanced Breast Cancer. *N Engl J Med* 2016; 375: 1925–36
11. Iwata H et al. PALOMA-3: Phase III Trial of Fulvestrant With or Without Palbociclib in Premenopausal and Postmenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer That Progressed on Prior Endocrine Therapy-Safety and Efficacy in Asian Patients. *J Glob Oncol* 2017; 3: 289–303
12. Sledge GW et al. MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy. *J Clin Oncol* 2017; 35: 2875–84
13. Baselga J et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. *N Engl J Med* 2012; 366: 520–29
14. Beck JT et al. Everolimus plus exemestane as first-line therapy in HR+, HER2- advanced breast cancer in BOLERO-2. *Breast Cancer Res Treat* 2014; 143: 459–67

15. Piccart M et al. Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2†. *Ann Oncol* 2014; 25: 2357–62
16. André F et al. Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer. *N Engl J Med* 2019; 380: 1929–40
17. André F et al. Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: final overall survival results from SOLAR-1. *Ann Oncol* 2021; 32: 208–17
18. Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. *Nature* 2012; 490: 61–70
19. Mollon LE et al. A Systematic Literature Review of the Prognostic and Predictive Value of PIK3CA Mutations in HR+/HER2- Metastatic Breast Cancer. *Clin Breast Cancer* 2020; 20: e232–e243
20. Goncalves MD, Hopkins BD, Cantley LC. Phosphatidylinositol 3-Kinase, Growth Disorders, and Cancer. *N Engl J Med* 2018; 379: 2052–62
21. Wagner U, Reuß A. S3-Leitlinie „Diagnostik, Therapie und Nachsorge maligner Ovarialtumoren“: Leitlinienprogramm Onkologie, Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF: Langversion 3.0, 2019, AWMF-Registernummer: 032/035OL. *Forum* 2019; 34
22. Robson M et al. Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation. *N Engl J Med* 2017; 377: 523–33
23. Litton JK et al. Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation. *N Engl J Med* 2018; 379: 753–63
24. Giordano SH et al. Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: American Society of Clinical Oncology clinical practice guideline. *J Clin Oncol* 2014; 32: 2078–99
25. Verma S et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. *N Engl J Med* 2012; 367: 1783–91
26. Cortés J et al. Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer. *N Engl J Med* 2022; 386: 1143–54
27. Modi S et al. Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer. *N Engl J Med* 2022
28. Murthy RK et al. Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer. *N Engl J Med* 2020; 382: 597–609
29. Cortes J et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. *Lancet* 2020; 396: 1817–28
30. Cortés J et al. LBA16 KEYNOTE-355: Final results from a randomized, double-blind phase III study of first-line pembrolizumab + chemotherapy vs placebo + chemotherapy for metastatic TNBC. *Ann Oncol* 2021; 32: S1289–S1290
31. Schmid P et al. Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. *N Engl J Med* 2018; 379: 2108–21
32. Miller K et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. *N Engl J Med* 2007; 357: 2666–76

33. Bardia A et al. Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer. *N Engl J Med* 2021; 384: 1529–41
  34. Zehir A et al. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. *Nat Med* 2017; 23: 703–13
  35. Mateo J et al. A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT). *Ann Oncol* 2018; 29: 1895–902
- 

## Update: Systemtherapie des fortgeschrittenen Nierenzellkarzinoms (S. 25–30)

*M. Johannsen, R. Eichenauer, J. Klier, F. König, R. Schönfelder und C. Doehn*

### **Literatur:**

1. Motzer RJ et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal cell carcinoma. *N Engl J Med* 2018; 378: 1277–90
2. Krege S & Doehn C. Fortgeschrittenes Nierenzellkarzinom: Neuerungen beim Einsatz zielgerichteter Therapien. *Dtsch Arztebl* 2021; 118(11): [6]
3. Heng D et al. External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. *Lancet Oncol* 2013; 14(2): 102–3
4. S3-Leitlinie Diagnostik, Therapie und Nachsorge des Nierenzellkarzinoms, Langversion 3.0, 2021, AWMF-Registernummer: 043/017OL, Stand: 01.04.2022
5. Mejean A et al. Sunitinib Alone or After Nephrectomy for Patients with Metastatic Renal Cell Carcinoma: Is There Still a Role for Cyto-reductive Nephrectomy? *Eur Urol.* 2021; 80(4): 417–24
6. Bex A et al. Comparison of immediate vs deferred cyto-reductive nephrectomy in patients with synchronous metastatic renal cell carcinoma receiving sunitinib: the SURTIME randomized clinical trial. *JAMA Oncol* 2019; 5(2): 164–70
7. Johannsen M et al. Can tyrosine kinase inhibitors be discontinued in patients with metastatic renal cell carcinoma and a complete response to treatment? A multicentre, retrospective analysis. *Eur Urol* 2009; 55(6): 1430–8
8. Johannsen M et al. Outcome of treatment discontinuation in patients with metastatic renal cell carcinoma and no evidence of disease following targeted therapy with or without metastasectomy. *Ann Oncol* 2011; 22(3): 657–63
9. Johannsen M. Therapie des Nierenzellkarzinoms mit Inhibitoren der Angiogenese. In: Johannsen M, Roigas J, Herausgeber. Nierenzellkarzinom und mTOR-Inhibition – Prinzipien und Perspektiven. UNI-MED SCIENCE, 1. Auflage, 2010; 18-25
10. Johannsen M & Doehn C. Checkpointinhibitor-basierte Kombinationstherapien. *UroNews* 2021; 25(4): 36–41
11. Motzer R et al. Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. *N Engl J Med* 2019; 380: 1103–15
12. Rini BI et al. Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. *N Engl J Med* 2019; 380: 1116–27

13. Choueiri T et al. Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma. *N Engl J Med* 2021; 384: 829–41
14. Motzer R et al. Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma. *N Engl J Med* 2021; 384: 1289–1300
15. Choueiri et al. Phase III Study of Cabozantinib (C) in Combination with Nivolumab (N) and Ipilimumab (I) in Previously Untreated Advanced Renal Cell Carcinoma (ARCC) of IMDC Intermediate or Poor Risk (COSMIC-313). *ESMO Abs.LBA8. Ann Oncol* 2022; 33: S1430–S1431
16. Motzer R et al. Nivolumab plus Cabozantinib versus Sunitinib in First-Line Treatment for Advanced Renal Cell Carcinoma (CheckMate 9ER): Long-Term Follow-up Results from an Open-Label, Randomised, Phase 3 Trial. *Lancet Oncol* 2022; 23: 888–98
17. Rini BI et al. Pembrolizumab (Pembro) plus Axitinib (Axi) versus Sunitinib as First-Line Therapy for Advanced Clear Cell Renal Cell Carcinoma (CcRCC): Results from 42-Month Follow-up of KEYNOTE-426. *J Clin Oncol* 2021; 39: 4500
18. Albiges et al. Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial. *ESMO Open* 2020; 5(6): e001079
19. Ciccarese C & Iacovelli R. Uncertainty Persists Regarding the Role of Immunotherapy for Treatment of Metastatic Renal Cell Carcinoma with Favourable Prognosis. *Eur Urol* 2022; S0302-2838(22)02782-8
20. Ljungberg B et al. European Association of Urology guidelines on renal cell carcinoma: the 2022 update. *Eur Urol* 2022; 82: 399–410
21. Motzer R et al. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. *N Engl J Med* 2015; 373(19): 1803–13
22. Choueiri TK et al. Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma. *N Engl J Med* 2015; 373(19): 1814–23
23. Motzer R et al. Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. *Lancet Oncol* 2015; 16(15): 1473–82
24. Lee CH et al. Phase II Trial of Cabozantinib Plus Nivolumab in Patients With Non-Clear-Cell Renal Cell Carcinoma and Genomic Correlates. *J Clin Oncol* 2022; 40(21): 2333–41
25. Albiges L et al. Phase II KEYNOTE-B61 study of pembrolizumab (Pembro) + lenvatinib (Lenva) as first-line treatment for non-clear cell renal cell carcinoma (nccRCC). *Ann Oncol* 2022; 33(suppl\_7): S660–S680
26. McDermott DF et al. CheckMate 214 Post-Hoc Analyses of Nivolumab plus Ipilimumab or Sunitinib in IMDC Intermediate/Poor-Risk Patients with Previously Untreated Advanced Renal Cell Carcinoma with Sarcomatoid Features. *J Clin Oncol* 2019; 37: 4513
27. Johannsen M et al. Nebenwirkungsmanagement der Checkpointinhibitor-Therapie. *UroNews* 2021; 25(4): 24–8
28. Heinzerling L et al. Checkpoint-Inhibitoren: Diagnostik und Therapie von Nebenwirkungen. *DtschArzteblInt* 2019; 116: 119–26
29. Grimm MO et al. Safe Use of Immune Checkpoint Inhibitors in the Multidisciplinary Management of Urological Cancer: The European Association of Urology Position in 2019. *EurUrol* 2019; 76: 368–80